| Bioactivity | GLS1 Inhibitor-1 (Compound 27) is an orally active inhibitor for glutaminase 1 (GLS1) with an IC50 of 0.021 μM. GLS1 Inhibitor-1 inhibits the proliferation of PC-3 with an IC50 of 0.0003 μM. GLS1 Inhibitor-1 exhibits antitumor efficacy against NCI-H1703 with GI50 of 0.011 μM. GLS1 Inhibitor-1 exhibits moderate pharmacokinetic characteristics[1]. |
| Target | IC50: 0.021 μM (GLS1) |
| CAS | 1832646-52-2 |
| Formula | C19H21N7O2S |
| Molar Mass | 411.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Finlay MRV, et al., Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models. J Med Chem. 2019 Jul 25;62(14):6540-6560. |
GLS1 Inhibitor-1
CAS: 1832646-52-2 F: C19H21N7O2S W: 411.48
GLS1 Inhibitor-1 (Compound 27) is an orally active inhibitor for glutaminase 1 (GLS1) with an IC50 of 0.021 μM. GLS1 In
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.